Option Care Health Q3 revenue slightly beats estimates

By Reuters News


Overview

  • US infusion services provider's Q3 revenue rose 4.1%, slightly beating analyst expectations

  • Q3 adjusted EBITDA beat analyst expectations


Outlook

  • Option Care Health has withdrawn its previously disclosed financial guidance due to pending acquisition


Result Drivers

  • REVENUE GROWTH - Q3 revenue increased 4.1% year-over-year

  • COSTS AND EXPENSES - Operating costs and expenses rose modestly, with higher selling, general and administrative expenses and increased restructuring and integration costs


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Slight Beat*

$1.49 bln

$1.48 bln (11 Analysts)

Q3 Net Income

$57.40 mln

Q3 Adjusted EBITDA

Beat

$124.60 mln

$123.30 mln (11 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 11 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy."

  • Wall Street's median 12-month price target for Option Care Health Inc is $32.00, about 0.7% above its November 3 closing price of $31.77

  • The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 12 three months ago


Reuters Recommended Reads

  • Nov 3 - Addus HomeCare Q3 adjusted EPS beats estimates; to acquire AccentCare personal care division

  • Nov 3 - AdaptHealth posts Q3 loss due to goodwill impairment charge

  • Nov 3 - Senior care provider InnovAge's Q1 revenue beats as participants increase


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.